Phase 2 single arm study to evaluate safety and efficacy of neoadjuvant short course radiotherapy along with chemotherapy followed by surgery in resectable carcinoma of esophagus

AIIMS Rishikesh0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Histologically Proven Esophageal or Gastroesophageal junction (Sievert 1 or 2) Carcinoma patients who are medically fit for surgery
•2.Stage II to IVA
•3.Age: 18-70 years
•4.ECOG: 0-2
•5.Normal hemodynamic indices before the recruitment (including white blood cell count >4.0Ã?109/L, neutrophil count >1.5Ã?109/L, platelet count >100Ã?109/L, hemoglobin>=90g/l, normal liver/kidney function)
•6.Able to understand this study and have signed informed consent.

•1. Have been previously treated with chemotherapy, radiotherapy and other anti-tumour treatment except surgery for non GI cancer
•2. Known or suspected allergy to paclitaxel or carboplatin;
•3. Female in pregnancy or lactating;
•4. Patients with significant psychological, family, social and other factors which may affect the ability to understand and sign the informed consent;
•5. Patients with peripheral neuropathy (CTC grade>=2);
•6. The patient not tolerant to neoadjuvant radiotherapy and chemotherapy for serious heart/lung/liver/kidney function, the haematopoietic system diseases, immune system diseases, nervous system diseases, cachexia, etc.

发起方